Osborne Clarke advises OncoDNA on its successful Round C financing

International legal practice Osborne Clarke advised OncoDNA on its Round C financing of €6.5 million.

OncoDNA is a genomic and theranostic company specializing in precision medicine for the treatment of patients with cancer and genetic diseases. This latest round of financing will support OncoDNA in achieving its goal of profitably and sustainable growth by providing personalized medicine. OncoDNA is a leader in the European bio-pharmaceutical sector, in part thanks to its unique OncoDEEP Kit, a pan-cancer genomic panel that utilizes the ability to locally perform the sequencing while benefiting from more than 100k profiles available in its central database developed since 2012. The results are readily available through the cloud-based, user friendly KDM interface.

Both private (including Vesalius BioCapital III, Ackermans & van Haaren, Swisscanto, CPH bank) and public (SFPI, Wallonie Entreprendre and Sambrinvest), along with management and long-time individual investors, have participated in this round of financing with the objective of supporting the Company in achieving its strategic plan.

The Osborne Clarke team was headed by partner Hadrien Chef and included Violette Keppenne, Laurent De Pauw and Mathilde Drion. Life sciences and healthcare are one of Osborne Clarke's key sector focuses. The experts in Brussels and the international network work daily with companies active in pharmaceuticals, biotech, medical technologies and digital health to navigate the legal and regulatory challenges around new trends and technologies for medicines, devices, diagnostics, social care and beyond.